|Bid||2.73 x 1000|
|Ask||3.00 x 1400|
|Day's Range||2.67 - 2.80|
|52 Week Range||1.47 - 6.06|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 18, 2017 - May 19, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
Celsion Corporation (CLSN), an oncology drug development company, today announced the appointment of Marianne Lambertson as Vice President of Communications and Investor Relations effective September 17, 2018. Ms. Lambertson most recently held the position of Vice President, Corporate Communications, Investor Relations/Public Relations at Verastem Oncology, a development-stage biopharmaceutical company.
Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...
Celsion Corporation (CLSN), an oncology drug development company, today announced it has begun dosing patients in the recently initiated OVATION II Study, the Company's randomized, Phase I/II clinical trial of GEN-1, its DNA-based immunotherapy for the localized treatment of ovarian cancer as an adjuvant to chemotherapy current standard of care. GEN-1, designed using Celsion's proprietary TheraPlas platform technology, is an interleukin-12 (IL-12) DNA plasmid vector encased in a non-viral nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. "In previous studies, GEN-1 was shown to be well tolerated at doses up to 79 mg/m2 with meaningful, dose-dependent, pro-immune clinical activity,” said Dr. Nicholas Borys, Celsion's senior vice president and chief medical officer. “The overall median progression-free survival (PFS) in the first OVATION Study recently reached 24 months among patients treated per protocol.
Celsion Corporation (CLSN), an oncology drug development company, today announced that it has reached its enrollment objective of 550 patients in the Company's pivotal, Phase III OPTIMA Study, a multinational, randomized, double-blind, placebo-controlled clinical trial of ThermoDox® in combination with radiofrequency ablation (RFA) for the treatment of patients with hepatocellular carcinoma (HCC), also known as primary liver cancer. The OPTIMA Study's design and statistical plan incorporates two pre-planned interim efficacy analyses by the study’s Data Monitoring Committee (DMC), and the first interim analysis is expected to occur in the first half of 2019.
NEW YORK, Sept. 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Celsion Corporation (CLSN), an oncology drug development company, today announced it has received approval from the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program to sell the Company’s unused New Jersey net operating losses (NOLs) and R&D tax credits for the tax years 2011 to 2017. The exact percentage of NOL’s to be sold will be determined by the NJEDA after reviewing all qualified applications.
NEW YORK, Aug. 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Celsion ...
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Celsion Corporation (NASDAQ: CLSN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 11:00 AM Eastern Time. ...
Strong Balance Sheet With Cash Sufficient to Fund Operations Into the First Half of 2020. Quarterly and Year-to-Date Cash Expenses Consistent With Prior Guidance Company to Hold Conference Call on Tuesday, ...
LAWRENCEVILLE, N.J, Aug. 07, 2018-- Celsion Corporation announced today that the Company will host a conference call to discuss financial results for the quarter ended June 30, 2018 and provide an update ...
Zacks.com highlights: Rosehill Resources, Navios Maritime Partners, AMC Entertainment Holdings, Entercom Communications and Celsion
Celsion Corporation (CLSN), an oncology drug development company, today announced that results from a Phase I trial of ThermoDox® were published in the peer-reviewed journal, The Lancet Oncology ¹. Conducted by a multi-disciplinary team of biomedical engineers, oncologists, radiologists and anesthetists at the University of Oxford, United Kingdom, the trial evaluated the safety and efficacy of ThermoDox®, Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin, along with focused ultrasound for the treatment of liver cancer.
Biotech stocks came under pressure earlier in the week, weighed down by negative trial results, mixed FDA verdicts and overall pessimistic broader market sentiment, but recovered in the last two sessions. ...
While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.
LAWRENCEVILLE, N.J., June 28, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (CLSN) (“Celsion” or “the Company”), an oncology drug development company, today announced that on June 27, 2018 it has entered into a $10 million loan agreement with Horizon Technology Finance Corporation (HRZN) ("Horizon") which it drew down upon closing. The Company anticipates that it will use the funding provided under the agreement for working capital and advancement of its product pipeline, including ThermoDox® for the treatment of hepatocellular carcinoma (“HCC”) and GEN-1 for the treatment of newly diagnosed ovarian cancer, as well as other strategic initiatives designed to broaden its product pipeline. "With our current cash position of $26 million after the funding of the new loan facility, we expect to have resources sufficient to fund current operations into the first half of 2020, including our ongoing pivotal Phase III HCC trial (the OPTIMA Study) and our Phase I/II ovarian cancer trial (the OVATION II Study).
Celsion Corporation (CLSN), an oncology drug development company, today announced that it will be added to the Russell Microcap® Index as part of the Russell indexes annual reconstitution, effective after the U.S. market opens today. FTSE Russell determines membership for its Russell U.S. Indexes primarily by objective, market-capitalization rankings and style attributes. Russell U.S. Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies.
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / U.S. equities slumped on Tuesday as global trade concerns grew after President Trump threatened to impose an additional $400 billion in tariffs on goods from ...
Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess Celsion Corporation’s (NASDAQ:CLSN) track record on a highRead More...
Most investors find it challenging to find companies with prospective double-digit growth rates that are also financially robust. These hidden gems also add meaningful upside to a portfolio, should theRead More...